Proteome Sciences Share Discussion Threads

[goatherd] 05/8/2024 18:18

That is the point Jeffian.

I believe that the clinical stroke is not very far away (months, not years) - and not before time.

I also believe that, once it is available, it will quickly become an essential test for all hospitals, worldwide.

We know that the price is just under £100 per test (for the research test; the clinical test may well be more); and we know that we (PRM) get at least 10%. So it is likely that our royalty will be close to £10 for every test.

So how many strokes?

"Stroke is a leading cause of death and disability worldwide. Globally, 1 in 4 adults over the age of 25 will have a stroke in their lifetime. Over 12 million people worldwide will have their first stroke this year and 6.5 million will die as a result. Over 100 million people in the world have experienced stroke."

Impact of Stroke - World Stroke Organization

If the test is only given once to every first-stroke victim that would give Proteome £120m royalty - for 100% coverage.
100% coverage sounds unlikely; but, if you consider

1. people who have only had a TIA
2. people who are retested during treatment (whicjh I am told, by medics, is highly likely.
3. people having other than their first stroke

then 100% could be near the final figure - it could even be higher!

[jeffian] 05/8/2024 17:01

My point being, Richard, that you can pick any old enormous figure out of the air (in fact, the PRM former forecast was supposed to be the result of research they commissioned) and imply that a company only has to get a very modest proportion of it to generate substantial revenues. Well, go on then.

[wellhonedhutch] 05/8/2024 16:22

And annually Richard.

[goatherd] 05/8/2024 16:15

Jeffian,

I think it all depends on who "they" are.

I have always thought that $10b was too high. IMHO $2b is in the right order.

Remember that we get at least 10% royalty.

[jeffian] 05/8/2024 15:49

"The market for stroke diagnosis in blood is WORTH OVER $2 BILLION A YEAR."

*whistles*

Wasn't there already a market of $10bn(?) they had identified a few years ago? How's that going?

[barry evans] 05/8/2024 10:05

Well done that secondary avatar, you almost managed to wait half an hour before following up your previous post.

[wasjobber] 05/8/2024 10:01

Proteome Sciences is an absolute "NO BRAINER" at this level.

The market for stroke diagnosis in blood is WORTH OVER $2 BILLION A YEAR.

When there is news, this will gap up significantly, well into double digits.

FILL YOUR BOOTS, BUY BUY BUY

[jeffian] 05/8/2024 09:47

Aye. I was wondering if "on the cusp" should be added to the Dictionary of Proteomespeak?

[pools2] 05/8/2024 09:37

Thanks Colinhy,

I understand that Randox are on the cusp of UKCA/CE registration for their stroke biochip test, which effectively 'converts' the current research test into the clinical stroke test.

The two products are exactly the same, no difference whatsoever. Except registration.

No registration = Research stroke test

UKCA/CE registration = Clinical stroke test

[elpirata] 05/8/2024 09:26

I think you should delete 'anytime soon'

[peverill] 05/8/2024 06:07

Going by Colin's new post,looks like the stroke test will not be released anytime soon commercially????.

[colinhy] 04/8/2024 17:00

Randox have completely revised their Stroke webpage.

It is now part of the Neurovascular Dysfunction Biochip which uses all of Proteome Sciences biomarkers for an increased number of disease areas and is currently used as a research tool.
-----------------------------------------
The Neurovascular Dysfunction Biochip gives clinicians a greater understanding of conditions involving disruption of the blood-brain barrier and associated vasculature. The biomarker panel is currently useful as a research tool for disease areas such as Epilepsy, Stroke Research, Brain Inflammation, Parkinson’s Disease, Alzheimer’s Disease, Down Syndrome, Brain Injury and Delirium.

Glutathione S-transferase Pi (GSTPi)
Parkinson Disease Protein 7 (PARK7)
Nucleoside Diphosphate Kinase A (NDKA)
Glial Fibrillary Acidic Protein (GFAP)
Fatty Acid Binding Protein 3 (FABP3)
Interleukin-6 (IL-6) 0 - 500 pg/mL
Soluble Tumour Necrosis Factor Receptor 1 (sTNFR1)
D-Dimer

[jeffian] 30/7/2024 21:12

Value = about 0.10p per plex then?

[wasjobber] 30/7/2024 18:04

With Steven Gygi joking that it is actually a 35-plex TMTpro set of reagents

New clinical 32-plex assays to be released

[peverill] 26/7/2024 11:44

Mariola in the job a few years now and done SFA for shareholders.infact the company going 30 years and done SFA for shareholders,killed a few off,aged many,while directors have done very well out of it.

[sandcrab2] 22/7/2024 11:27

The excellent Fgnoms covered this 13 years ago

“fgnoms30 Apr '11 - 10:28 - 14 of 26
0 0 0
Well here we are at the end of April and still no commercial money-making contracts have been signed. CJP at the time of the money raising reiterated break even for 2010, which would have required a few such contracts to have been signed in say late Q3 2010. So seven months on and NO such deals have been signed. I guess the important question is why? Of course we have suffered the same sorry story for the last 4 years on stroke. Yes 4 years ago contracts were imminent and apparently still are but we haven't been told why they haven't been signed. The obvious explanation is that PRM stroke biomarkers together with other panel constituents don't work well enough and therefore a stroke panel cannot be commercialised. Remember all those companies testing the PRM stroke biomarkers - and absolutely nothing has resulted. I think it would now be reasonable to assume that stroke is dead. So what about AD. Yes we are now at the same stage as stroke was 4 years ago. Tests are being carried out - but this time by PRM itself. This indicates to me that none of the big boys have any faith whatsoever in PRM's AD biomarkers - especially since the Dutch revelation that Clusterin isn't a predictive biomarker. So why does PRM continue to lead us on that a commercial deal is just around the corner. I find this bizarre. As PRM is now carrying out its own tests on its own panel nobody is going to sign anything until the results are known - which will probably be in H1 2012. And even then it really isn't feasible that a final saleable AD working panel will only contain PRM biomarkers, is it? So in my view we are years away from a working AD panel. So where does all this optimism come from - cloud cuckoo land imho.

So before my next post we will know the 2010 results - a complete disaster no doubt. A loss of nearly £5m compared with target breakeven. 2011 is also looking like another £5m loss as I don't believe any commercial contracts will be signed. 2012 may not be much better either and thats when the cash runs out. So what will the share price be when all this is revealed next month? A very far cry from anything the rampers are saying thats for sure.”

[monte1] 22/7/2024 10:23

Thanks goatherd.

[barry evans] 22/7/2024 09:51

re 92987

For the benefit of those that have the avatar goatherd filtered and will not have been able to view this (It is quite something):


wasjobber 22 Jul '24 - 10:18 - 59772 of 59774 0 1 0

I wonder how high Proteome Sciences share price will rise after Randox announce the release of their clinical Stroke test in blood?


pools2 22 Jul '24 - 10:31 - 59773 of 59774 0 0 0

wasjobber,

PRM's share price should rise significantly after Randoz release their clinical Stroke test. It could also rise before the release date.


wasjobber 22 Jul '24 - 10:43 - 59774 of 59774 0 0 0

Thanks pools2

[jeffian] 22/7/2024 09:44

As it is in the public domain and has been 'anticipated' for years, surely it is already in the price?

[wasjobber] 22/7/2024 09:43

Thanks pools2

[peverill] 22/7/2024 09:42

And why are two Avatars of the same person talking to each other over on the boring thread.No amount of ramping will move anything here,just cold hard stroke/AD news.

[pools2] 22/7/2024 09:31

wasjobber,

PRM's share price should rise significantly after Randoz release their clinical Stroke test. It could also rise before the release date.

[wasjobber] 22/7/2024 09:18

I wonder how high Proteome Sciences share price will rise after Randox announce the release of their clinical Stroke test in blood?

[monte1] 22/7/2024 09:16

Let’s hope it is to the moon, the stars and beyond.

That said it may be rather unwise to hold one’s breath on that hope or expectation.